Adalimumab combined with Dexamethasone intravitreal implant in the treatment of refractory noninfectious uveitis macular edema
10.3980/j.issn.1672-5123.2024.1.07
- VernacularTitle:阿达木单抗联合地塞米松玻璃体腔植入剂治疗难治性非感染性葡萄膜炎性黄斑水肿
- Author:
Yuan SUI
1
;
Jingwen SUN
1
;
Chengsen ZHANG
1
;
Xueli LI
1
;
Xiaomei GOU
1
Author Information
1. Department of Ophthalmology, Harbin 242 Hospital, Harbin 150000, Heilongjiang Province, China
- Publication Type:Journal Article
- Keywords:
uveitis macular edema;
Adalimumab;
Dexamethasone intravitreal implant;
Helper T cell 17/regulatory T cell
- From:
International Eye Science
2024;24(1):36-41
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the effect of adalimumab combined with dexamethasone intravitreal implant in the treatment of refractory non-infectious uveitis macular edema(UME).METHODS: A total of 92 cases(131 eyes)of refractory non-infectious UME patients admitted to our hospital from January 2020 to January 2022 were selected and randomly divided into control group, with 46 cases(63 eyes)treated with dexamethasone intravitreal implant and observation group, with 46 cases(68 eyes)treated with adalimumab subcutaneous injection combined with dexamethasone intravitreal implant. The best corrected visual acuity(BCVA), central retinal thickness(CRT), vitreous opacity and Th17/Treg cytokines were measured before and after treatment, and the occurrence of adverse reactions was recorded.RESULTS: Totally 3 cases(4 eyes)were lost to follow-up. After treatment for 1, 3, 6 and 12 mo, BCVA was improved in both groups compared with that before treatment, and CRT, vitreous opacity score, serum interleukin(IL)-17 and IL-22 levels were decreased compared with those before treatment, and serum transforming growth factor-β(TGF-β)and IL-10 levels were increased compared with those before treatment. BCVA in the observation group was better than that in the control group, and CRT, vitreous opacity score, serum IL-17 and IL-22 levels were lower than those in the control group, and serum TGF-β and IL-10 levels were higher than those in the control group(all P<0.05). During treatment and follow-up, no serious adverse reactions occurred in both groups.CONCLUSION: Adalimumab combined with dexamethasone intravitreal implants in the treatment of refractory non-infectious UME can significantly subside the macular edema, reduce vitreous opacity and improve visual acuity.
